What is BfArM?

Germany's Federal Institute for Drugs and Medical Devices (BfArM) is a federal authority within the Federal Ministry of Health's remit. Its responsibilities particularly include medicine authorization within its jurisdiction, pharmacovigilance and assessment of medical-device risks.

It participates in the European regulatory network. It is nevertheless neither solely responsible for all medicines nor a general marketing-authorization authority for devices. Legislators establish the statutory framework; BfArM performs its assigned functions.

What are its medicines responsibilities?

BfArM assesses information concerning medicine quality, efficacy and safety. The Paul-Ehrlich-Institut's product responsibilities and centralized EU procedures must be distinguished. In centralized procedures, EMA performs the scientific assessment and the European Commission makes the authorization decision.

Safety information continues to be assessed after authorization. New findings may require updated product information or further risk-minimization measures. Clinical trials additionally have their own authorization and ethics procedures; simple notification is not generally sufficient.

What is its role for devices and DiGA?

Device responsibilities particularly include risk assessment and specified decisions about legal status and classification. Normal device market access generally involves conformity assessment and CE marking. BfArM does not itself issue CE marks.

It also maintains the DiGA directory and assesses applications through the relevant procedure. Directory inclusion is separate from an application's classification as a device and its CE marking. Not every health application is a reimbursable DiGA.

Which resources help marketing teams?

Public safety communications, approved educational materials and medicines information help maintain current content. The official DiGA directory allows teams to check the particular listing. Claims should concern the application actually listed and its status.

Regulatory advice can support development, but it does not approve advertising or guarantee commercial success. Marketing teams should check product status, permitted statements and safety changes with the responsible internal functions.

Conclusion: Match responsibilities with the right evidence

BfArM is an important source of regulatory and safety information. Its role differs for medicines, devices and DiGA. Accurate attribution avoids false descriptions of official authorization and health-related safety.